de Sanctis C, Lala R, Canavese F
Divisione di Endocrinologia Pediatrica, Ospedale Infantile Regina Margherita Istituti Universitari di Pediatria di Torino, Italia.
Pediatr Med Chir. 1995 Jan-Feb;17(1):23-8.
Cryptorchidism is the most frequent anomaly of an endocrine gland; it entails risks of infertility and testicular cancer. Its pathogenesis is thought to be multifactorial including anatomical and mechanical together with endocrine causes. In the last decades most Authors favoured the hypothesis that some degree of androgen insufficiency during fetal life may play a role in determining testicular maldescent. Morphological alterations have been demonstrated in cryptorchidism testes since birth; both tubular and interstitial damage already can be found in the first months of life. A critical phase in germinal development occurs during the third month when gonadotropin and testosterone postnatal surge induces the first maturational step in germ cells development. In cryptorchid infants, gonadotropin insufficiency at this time reduces germ cells differentiation, leading to progressive germinal decline, which becomes manifest after 12 months of life. In the opinion of some Authors, germinal alteration can be partially reversed by early scrotal reposition of the cryptorchid testes. Hormonal therapy with human chorionic gonadotropin (HCG) and luteinizing hormone releasing hormone (LHRH) has been used in the past decades with variable results. A combination of the two hormones has had a greater effect in inducing testicular descent compared to single hormone treatment. Although some surgeons already treat cryptorchid patients during childhood, an increasing number of pediatric surgeons believe that early treatment, performed during infancy is preferable, when considering the early and progressive histological damage seen in cryptorchid gonads. In our opinion, also hormonal treatment performed during the first year of life seems preferable since it can at the same time induce scrotal descent of cryptorchid testes and substitute postnatal gonadotropin insufficiency.
隐睾症是内分泌腺最常见的异常情况;它会带来不育和睾丸癌的风险。其发病机制被认为是多因素的,包括解剖学、机械性以及内分泌原因。在过去几十年中,大多数作者支持这样一种假说,即胎儿期某种程度的雄激素不足可能在睾丸下降异常的发生中起作用。自出生以来,隐睾症患者的睾丸已被证实存在形态学改变;在生命的头几个月就可以发现曲细精管和间质的损伤。生殖细胞发育的关键阶段发生在第三个月,此时促性腺激素和睾酮的出生后激增诱导生殖细胞发育的第一步成熟。在隐睾症患儿中,此时促性腺激素不足会减少生殖细胞分化,导致生殖细胞逐渐减少,这在12个月大时变得明显。一些作者认为,通过早期将隐睾睾丸阴囊复位,生殖细胞的改变可以部分逆转。在过去几十年中,已使用人绒毛膜促性腺激素(HCG)和促黄体生成素释放激素(LHRH)进行激素治疗,结果不一。与单一激素治疗相比,两种激素联合使用在诱导睾丸下降方面效果更佳。尽管一些外科医生已经在儿童期治疗隐睾症患者,但越来越多的小儿外科医生认为,考虑到隐睾性腺早期和渐进性的组织学损伤,在婴儿期进行早期治疗更为可取。我们认为,在生命的第一年进行激素治疗似乎也更可取,因为它可以同时促使隐睾睾丸降至阴囊,并弥补出生后促性腺激素不足。